A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Summary

This is a study to determine the safety of multiple doses of CDX-0159 in patients with Chronic Spontaneous Urticaria.

Timeline

Start

2020-09-24

Primary completion

2023-01-17

Completion

2023-01-17

Outcome

Met primary endpoint

release “Barzolvolimab results in rapid, marked and durable responses in patients with moderate to severe CSU refractory to antihistamines, including patients with prior omalizumab treatment.” celldex.com ↗

Drugs

Indications